Skip to main content

Compare Stocks

Date Range: 

 Fortress BiotechUroGen PharmaFlexion TherapeuticsXOMAMedAvail
SymbolNASDAQ:FBIONASDAQ:URGNNASDAQ:FLXNNASDAQ:XOMANASDAQ:MDVL
Price Information
Current Price$3.68$15.20$8.24$29.92$11.35
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.81.41.51.9
Analysis Score4.53.53.53.53.5
Community Score2.73.03.02.53.6
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.81.7
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$10.80$40.50$20.11$46.00$20.00
% Upside from Price Target193.48% upside166.45% upside144.22% upside53.74% upside76.21% upside
Trade Information
Market Cap$357.90 million$317.63 million$411.27 million$337.20 million$362.59 million
Beta2.431.321.641.261.2
Average Volume1,539,544186,906872,98749,76887,535
Sales & Book Value
Annual Revenue$36.63 million$20,000.00$72.96 million$18.37 million$1.03 million
Price / Sales9.7715,881.725.6418.36352.03
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.02 per share$8.63 per share($0.53) per share$5.03 per share$1.54 per share
Price / Book3.611.76-15.545.957.37
Profitability
Net Income$-39,960,000.00$-105,150,000.00$-149,770,000.00$-1,980,000.00$-4,260,000.00
EPS($0.73)($5.12)($3.93)($0.23)($5.52)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-131.98%N/A-153.90%-102.23%-245.38%
Return on Equity (ROE)-44.08%-92.22%N/A-28.83%-168.39%
Return on Assets (ROA)-19.06%-81.71%-53.31%-11.91%-104.11%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.29%N/A12.77%0.61%0.15%
Current Ratio6.38%7.34%4.66%4.63%2.71%
Quick Ratio6.35%7.26%4.31%4.63%1.11%
Ownership Information
Institutional Ownership Percentage32.13%71.60%N/A57.21%40.24%
Insider Ownership Percentage29.50%12.00%17.03%9.89%45.30%
Miscellaneous
Employees11118725710137
Shares Outstanding97.25 million20.90 million49.94 million11.27 million31.95 million
Next Earnings Date5/17/2021 (Estimated)8/9/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
MedAvail Holdings (MDVL) CEO Ed Kilroy on Q1 2021 Results - Earnings Call TranscriptMedAvail Holdings' (MDVL) CEO Ed Kilroy on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 9:15 AM
MedAvail (NASDAQ:MDVL) Releases Quarterly  Earnings Results, Beats Estimates By $0.01 EPSMedAvail (NASDAQ:MDVL) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
americanbankingnews.com - May 13 at 7:58 PM
MedAvail (NASDAQ:MDVL) Releases FY 2021 Earnings GuidanceMedAvail (NASDAQ:MDVL) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 5:50 PM
MedAvail Reports First Quarter 2021 Financial ResultsMedAvail Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 12 at 5:37 PM
MedAvail (MDVL) Set to Announce Quarterly Earnings on WednesdayMedAvail (MDVL) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - May 5 at 6:42 AM
MedAvail to Report 2021 First Quarter Financial Results on May 12, 2021MedAvail to Report 2021 First Quarter Financial Results on May 12, 2021
finance.yahoo.com - April 28 at 5:38 PM
MedAvail (NASDAQ:MDVL) Updates FY 2021 Earnings GuidanceMedAvail (NASDAQ:MDVL) Updates FY 2021 Earnings Guidance
americanbankingnews.com - April 28 at 3:12 PM
 Brokerages Anticipate MedAvail Holdings, Inc (NASDAQ:MDVL) to Post -$0.30 EPS Brokerages Anticipate MedAvail Holdings, Inc (NASDAQ:MDVL) to Post -$0.30 EPS
americanbankingnews.com - April 27 at 2:18 PM
MedAvail Announces Continued Expansion of Its Technology Agreement With a North Texas Health SystemMedAvail Announces Continued Expansion of Its Technology Agreement With a North Texas Health System
finance.yahoo.com - April 14 at 8:02 PM
18,00318,003
businesswire.com - March 31 at 12:54 AM
MedAvail Reports Fourth Quarter and Full Year 2020 Financial ResultsMedAvail Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 30 at 7:53 PM
MedAvail to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021MedAvail to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
finance.yahoo.com - March 16 at 6:14 PM
TMCOne Continues to Expand Relationship with MedAvail, Offering Integrated In-Clinic Pharmacy Experience in Multiple LocationsTMCOne Continues to Expand Relationship with MedAvail, Offering Integrated In-Clinic Pharmacy Experience in Multiple Locations
finance.yahoo.com - March 2 at 8:53 AM
MYOS CORP Secures Fourth Patent as Part of R&D Drive to Address Healthcare Burden of Sarcopenia and Muscle-Related DisordersMYOS CORP Secures Fourth Patent as Part of R&D Drive to Address Healthcare Burden of Sarcopenia and Muscle-Related Disorders
finance.yahoo.com - February 24 at 1:38 PM
MedAvail Holdings, Incs (NASDAQ:MDVL) Intrinsic Value Is Potentially 48% Above Its Share PriceMedAvail Holdings, Inc's (NASDAQ:MDVL) Intrinsic Value Is Potentially 48% Above Its Share Price
finance.yahoo.com - February 22 at 8:47 AM
MedAvail Announces Preliminary Fourth Quarter and Full Year 2020 ResultsMedAvail Announces Preliminary Fourth Quarter and Full Year 2020 Results
finance.yahoo.com - February 17 at 8:16 AM
Stock Alert: MedAvail Holdings Up 5% On Partnership With Cigna Medical GroupStock Alert: MedAvail Holdings Up 5% On Partnership With Cigna Medical Group
nasdaq.com - February 9 at 1:36 PM
MedAvail’s SpotRx Pharmacy and Cigna Medical Group Partner to Help Improve Medication Access in PhoenixMedAvail’s SpotRx Pharmacy and Cigna Medical Group Partner to Help Improve Medication Access in Phoenix
finance.yahoo.com - February 9 at 1:36 PM
MedAvail to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceMedAvail to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
finance.yahoo.com - February 3 at 8:50 AM
MedAvail Enters Michigan MarketMedAvail Enters Michigan Market
finance.yahoo.com - January 11 at 5:08 PM
MedAvail to Present at the 39th Annual J.P. Morgan Healthcare ConferenceMedAvail to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 10:07 AM
MemorialCare Continues to Expand Relationship with MedAvail, Offering Integrated In-Clinic Pharmacy Experience in Multiple LocationsMemorialCare Continues to Expand Relationship with MedAvail, Offering Integrated In-Clinic Pharmacy Experience in Multiple Locations
finance.yahoo.com - December 11 at 4:25 PM
DateCompanyBrokerageAction
4/26/2021Fortress BiotechRoth CapitalBoost Price Target
4/5/2021Fortress BiotechB. RileyReiterated Rating
4/1/2021Fortress BiotechCantor FitzgeraldReiterated Rating
2/26/2021Fortress BiotechHC WainwrightReiterated Rating
2/17/2021Fortress BiotechDawson JamesBoost Price Target
10/2/2020Fortress BiotechBenchmarkInitiated Coverage
5/21/2018Fortress BiotechJMP SecuritiesSet Price Target
11/10/2020UroGen PharmaOppenheimerLower Price Target
9/21/2020UroGen PharmaJPMorgan Chase & Co.Lower Price Target
8/10/2020UroGen PharmaStifel NicolausReiterated Rating
1/16/2020UroGen PharmaCowenReiterated Rating
1/9/2020UroGen PharmaNational SecuritiesInitiated Coverage
5/13/2021Flexion TherapeuticsCredit Suisse GroupLower Price Target
4/20/2021Flexion TherapeuticsRaymond JamesLower Price Target
4/18/2021Flexion TherapeuticsRoyal Bank of CanadaReiterated Rating
1/27/2021Flexion TherapeuticsWells Fargo & CompanyLower Price Target
12/14/2020Flexion TherapeuticsNeedham & Company LLCReiterated Rating
11/5/2020Flexion TherapeuticsBMO Capital MarketsLower Price Target
8/20/2020Flexion TherapeuticsThe Goldman Sachs GroupInitiated Coverage
8/6/2020Flexion TherapeuticsNorthland SecuritiesInitiated Coverage
5/26/2020Flexion TherapeuticsGuggenheimInitiated Coverage
11/25/2020XOMAWedbushReiterated Rating
8/14/2018XOMAS&P Equity ResearchLower Price Target
12/14/2020MedAvailLake Street CapitalInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.